Researchers from the University of British Columbia and Vancouver Coastal Health Research Institute have found that a widely prescribed drug for multiple sclerosis (MS) is associated with longer survival for patients.
Mar 18, 2019
0
438
A newfound genetic regulatory mechanism may shape the immune system's ability to fight viral infections, and play a key role in autoimmune diseases that occur when immune cells attack bodily tissues.
Nov 27, 2018
0
112
The human heart is particularly vulnerable to viruses. That's because cardiac myocytes, the heart muscle cells that give your heart its ability to "beat," have one major weakness – they don't reproduce themselves to repair ...
Sep 29, 2017
0
36
Since its approval in 2011, the multiple sclerosis drug fingolimod (Gilenya) has already undergone three early benefit assessments, all of which were mainly based on the approval study TRANSFORMS. After a new modification ...
Mar 08, 2016
0
9
Pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed fingolimod (trade name: Gilenya), a drug for the treatment ...
Jul 06, 2015
0
11
A new study led by investigators at Brigham and Women's Hospital (BWH) reports the discovery of a genetic variant that is associated with a patient's likelihood of responding to interferon-beta, one of the medications used ...
May 14, 2015
0
93
The immunosuppressive drug fingolimod (trade name: Gilenya) was approved for an expanded therapeutic indication in May 2014: It is now also available for adults with highly active relapsing remitting multiple sclerosis (RRMS) ...
Oct 10, 2014
0
0
Tests of a new long-acting version of one of the oldest multiple sclerosis (MS) drugs on the market show it worked significantly better than placebo in reducing the number of patient relapses and developments of new or active ...
Apr 30, 2014
0
0
(HealthDay)—There has been an unusually high number of cases of thrombotic microangiopathy associated with severe or malignant hypertension in patients with multiple sclerosis who were receiving therapy with recombinant ...
Mar 27, 2014
0
0
Monash University researchers have gained new insight into the early stages of our immune response, providing novel pathways to develop treatments for diseases from multiple sclerosis to cancer.
Jul 21, 2013
0
0
